ReviewCurrent opinion in HIV and AIDS2020
Polypharmacy in HIV: recent insights and future directions.
Review in Current opinion in HIV and AIDS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis.Journal of comparative effectiveness research · 2026Pooled it
- Developing an HIV-specific falls risk prediction model with a novel clinical index: a systematic review and meta-analysis method.BMC infectious diseases · 2024Pooled it
- Experience of chronic noncommunicable disease in people living with HIV: a systematic review and meta-aggregation of qualitative studies.BMC public health · 2021Pooled it
- Guideline
- Moderate-to-Vigorous Physical Activity, Muscle Function, and Contemporary Sarcopenia Definitions in Older Adults With HIV.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Smoldering in the sanctuary: HIV-associated brain injury in the ART era.The Journal of clinical investigation · 2026Review
- A Case-Control Study of Virologic Failure Among People Living with HIV Enrolled in a NYC-Based Medicaid Special Needs Plan.AIDS and behavior · 2026Article
- PAIRED: Quantitative and Qualitative PAtIent-Reported Experiences and perceiveD Benefit of Treatment with Dolutegravir/Lamivudine in the United States.The patient · 2026Article
- Polypharmacy in HIV: Rethinking what counts and why it matters.HIV medicine · 2026Review
- High prevalence of polypharmacy and nervous system medications in people with HIV: a cross-sectional analysis.Scientific reports · 2026Article
- Type 2 diabetes in people living with HIV: epidemiology, mechanisms, sex differences and early-life determinants.Frontiers in endocrinology · 2026Review
- Longitudinal effects of polypharmacy on cognitive function in people with HIV.AIDS (London, England) · 2026Article
- Treatment of Advanced HIV in the Modern Era.Drugs · 2025Review
- The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study.Journal of general internal medicine · 2024Observational
- The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance.BMC infectious diseases · 2024Article
- Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study.Infectious diseases and therapy · 2024Article
- Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier.Fluids and barriers of the CNS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewUpdate findings regarding polypharmacy among people with HIV (PWH) and consider what research is most needed. RECENT
findingsAmong PWH, polypharmacy is common, occurs in middle age, and is predominantly driven by nonantiretroviral (ARV) medications. Many studies have demonstrated strong associations between polypharmacy and receipt of potentially inappropriate medications (PIMS), but few have considered actual adverse events. Falls, delirium, pneumonia, hospitalization, and mortality are associated with polypharmacy among PWH and risks remain after adjustment for severity of illness. SUMMARY: Polypharmacy is a growing problem and mechanisms of injury likely include potentially inappropriate medications, total drug burden, known pairwise drug interactions, higher level drug interactions, drug--gene interactions, and drug--substance use interactions (alcohol, extra-medical prescription medication, and drug use). Before we can effectively design interventions, we need to use observational data to gain a better understanding of the modifiable mechanisms of injury. As sicker individuals take more medications, analyses must account for severity of illness. As self-report of substance use may be inaccurate, direct biomarkers, such as phosphatidylethanol (PEth) for alcohol are needed. Large samples including electronic health records, genetics, accurate measures of substance use, and state of the art statistical and artificial intelligence techniques are needed to advance our understanding and inform clinical management of polypharmacy in PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.